Comparative Pharmacology
Head-to-head clinical analysis: EXONDYS 51 versus QALSODY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXONDYS 51 versus QALSODY.
EXONDYS 51 vs QALSODY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antisense oligonucleotide that binds to exon 51 of dystrophin pre-mRNA, inducing skipping of exon 51 during splicing to restore the reading frame and produce a truncated but functional dystrophin protein in patients with Duchenne muscular dystrophy (DMD) who have confirmed mutations amenable to exon 51 skipping.
QALSODY (tofersen) is an antisense oligonucleotide that mediates degradation of SOD1 mRNA through RNase H activity, reducing SOD1 protein production.
30 mg/kg intravenously over 35-60 minutes once weekly
100 mg intrathecally once every 4 weeks. Administer as a loading dose of 100 mg on days 0, 14, and 28, then every 4 weeks thereafter.
None Documented
None Documented
Terminal elimination half-life is approximately 28-32 days. This long half-life supports weekly dosing intervals.
Terminal elimination half-life is approximately 28 days (range 22-35 days) following intrathecal administration; this prolonged half-life supports monthly dosing schedules and reflects slow clearance from the central nervous system.
Primarily eliminated via renal excretion as intact oligonucleotide. Approximately 30-40% of administered dose is excreted unchanged in urine within 24 hours. No significant biliary or fecal elimination.
Primarily excreted unchanged in urine via glomerular filtration and tubular secretion, accounting for approximately 60-70% of the administered dose; biliary/fecal excretion accounts for the remainder (30-40%) as inactive metabolites and parent drug.
Category C
Category C
Antisense Oligonucleotide
Antisense Oligonucleotide